Three independent discounted-cash-flow-style models value BioMarin Pharmaceuticals Inc every trading day. 0 of 3 currently price BMRN above its market price.
| Free Cash Flow model | $10.29 |
| Excess Profit model | $19.71 |
| Residual Earnings model | $-1.00 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +4.7% |
| Net debt / EBITDA | -1.4× |
| Gross margin | +77.7% |
| Revenue CAGR | +15.4% |
| Cash conversion | 2.4× |
| Dividend yield | — |
| Buyback yield | -0.9% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open BMRN in StockKitty